Date of Presentation
5-6-2021 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Introduction
- Multiple myeloma (MM) is a cancer of plasma cells, which is a white blood cell that normally produces antibodies
- Treatment in patients younger than 65 years old is typically high dose chemotherapy, usually with bortezomib based regimens or lenalidomide dexamethasone, followed by a stem cell transplant
- For patients with relapsed myeloma, carfilzomib is usually the treatment of choice
- Carfilzomib is a highly selective, irreversible proteasome inhibitor that binds to the 20 S proteasome. Several studies have illustrated that carfilzomib has been associated with cardiovascular adverse events (CVAE).
- Current literature on the role and effect of bortezomib on cardiotoxicity is contradictory
- Past studies have shown benefits of using carfilzomib in MM patients, leading to improved response rates and overall survival
- There is scarce research on the risk factors associated with the development of cardiotoxicity with carfilzomib
Objective
To determine the incidence of cardiovascular adverse events (CVAE) associated with carfilzomib and bortezomib utilization and to assess risk factors for carfilzomib related cardiotoxicity
Keywords
Multiple Myeloma, Cardiotoxicity, carfilzomib, bortezomib
Disciplines
Cardiology | Hematology | Hemic and Lymphatic Diseases | Immune System Diseases | Medicine and Health Sciences | Neoplasms | Oncology | Pathological Conditions, Signs and Symptoms | Pharmaceutical Preparations
Document Type
Poster
Included in
Cardiology Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Immune System Diseases Commons, Neoplasms Commons, Oncology Commons, Pathological Conditions, Signs and Symptoms Commons, Pharmaceutical Preparations Commons
The Effect of Carfilzomib and Bortezomib Based Regimes on Cardiotoxicity in Multiple Myeloma Patients at Cooper University Hospital
Introduction
- Multiple myeloma (MM) is a cancer of plasma cells, which is a white blood cell that normally produces antibodies
- Treatment in patients younger than 65 years old is typically high dose chemotherapy, usually with bortezomib based regimens or lenalidomide dexamethasone, followed by a stem cell transplant
- For patients with relapsed myeloma, carfilzomib is usually the treatment of choice
- Carfilzomib is a highly selective, irreversible proteasome inhibitor that binds to the 20 S proteasome. Several studies have illustrated that carfilzomib has been associated with cardiovascular adverse events (CVAE).
- Current literature on the role and effect of bortezomib on cardiotoxicity is contradictory
- Past studies have shown benefits of using carfilzomib in MM patients, leading to improved response rates and overall survival
- There is scarce research on the risk factors associated with the development of cardiotoxicity with carfilzomib
Objective
To determine the incidence of cardiovascular adverse events (CVAE) associated with carfilzomib and bortezomib utilization and to assess risk factors for carfilzomib related cardiotoxicity